- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation ...
Allogene Therapeutics (ALLO) announced an update on their ongoing clinical study. The ALPHA study, officially titled A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results